4 completed, 2 terminated. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow AB Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Miltefosine - PKDL | Phase 2 | Completed | AB Foundation | 37 | 2007-07-01 | 2012-07-10 |
| Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony Miltefosine and antimony, Miltefosine alone - Cutaneous Leishmaniasis | Phase 2 | Terminated | Foundation Fader | 19 | 2007-03-01 | 2011-06-27 |
| Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia miltefosine, antimony - Cutaneous Leishmaniasis | Phase 2 | Completed | AB Foundation | 80 | 2005-09-01 | 2010-06-02 |
| Miltefosine for Brazilian Visceral Leishmaniasis Miltefosine: initially 2.5 mg/kg/day for 28 days - Kala Azar | Phase 1 / Phase 2 | Terminated | AB Foundation | 80 | 2005-04-01 | 2016-07-12 |
| Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis miltefosine: 2.5 mg/kg/day for 42 days - Leishmaniasis | Phase 1 / Phase 2 | Completed | AB Foundation | 25 | 2005-04-01 | 2010-06-02 |
| Miltefosine for Mucosal Leishmaniasis miltefosine 2.5 mg/kg/day for 28 days - Leishmaniasis | Phase 1 / Phase 2 | Completed | AB Foundation | 75 | 2004-04-01 | 2006-09-08 |
Leishmaniasis (4) · Leishmaniasis, Cutaneous (2) · Leishmaniasis, Visceral (1)
miltefosine (5) · Antimony (2)
Bolivia (4) · Brazil (1) · India (1)
J Soto, MD (1) · Jaime Soto, MD (1) · Reynaldo Dietze (1)